机译:患有活动性或先前结核病的成人中腺病毒35结核疫苗候选者的安全性和免疫原性随机试验
University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine;
University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine;
University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine;
University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine;
UCLA Medical Centre, Los Angeles, California;
Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands;
Crucell Holland B.V., a Janssen Pharmaceutical company of Johnson & Johnson, Leiden, the Netherlands;
Crucell Holland B.V., a Janssen Pharmaceutical company of Johnson & Johnson, Leiden, the Netherlands;
Crucell Holland B.V., a Janssen Pharmaceutical company of Johnson & Johnson, Leiden, the Netherlands;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
Aeras, Rockville, Maryland;
South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology,Vaccines for Africa Initiative, Division of Medical Microbiology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa;
South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology,Singapore Immunology Network, Agency for Science, Technology and Research, Singapore;
South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology;
South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology;
University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine;
tuberculosis; TB vaccine; vaccine safety; pulmonary complications; vaccine immunogenicity;
机译:HIV阳性印度成年人中M72 / AS01候选结核病疫苗的随机,对照安全性和免疫原性试验。
机译:艾滋病毒阳性印度成年人的M72 / AS01候选结核病疫苗随机,受控安全性和免疫原性试验
机译:M72 / AS01候选结核病疫苗在HIV感染的成年人中联合抗逆转录病毒疗法的安全性和免疫原性:I / II期,随机试验(第28卷,第1769页,2014年)
机译:一种双盲,随机期II试验,对健康成人的26岁的26岁群体的疫苗疫苗
机译:在南非东开普省进行的一项分组随机干预试验,评估了“选择退出”与“选择加入”策略对艾滋病毒咨询和结核病患者检测的接受程度。
机译:HIV阳性印度成年人中M72 / AS01候选结核病疫苗的随机对照安全性和免疫原性试验。
机译:M72 / AS01E候选结核病疫苗的长期安全性和免疫原性在艾滋病毒阳性和阴印的成人中:II期随机对照试验的结果:错误